AKTIS ONCOLOGY INC (AKTS)
Health Care · Targeted radiopharmaceuticals / radiotherapy oncology · NASDAQ
Aktis Oncology is developing next-generation targeted radiopharmaceuticals using a proprietary miniprotein platform to deliver alpha-emitting radioisotopes to hard-to-treat solid tumors.
What AKTIS ONCOLOGY INC does
Aktis Oncology is a clinical-stage oncology company focused on developing targeted radiopharmaceuticals using proprietary miniprotein radioconjugate technology. The company's lead program targets Nectin-4 with [225Ac]Ac-AKY-1189, a miniprotein conjugated to the alpha-emitting radioisotope actinium-225, designed for treatment of locally advanced or metastatic urothelial cancer and other Nectin-4-expressing solid tumors. Aktis is building end-to-end supply capabilities and manufacturing infrastructure to support clinical development and potential commercial deployment of its radiopharmaceutical pipeline across multiple tumor types.
Themes: Radiopharmaceuticals / targeted radiotherapy, Oncology / cancer immunotherapy, Urothelial cancer, Solid tumor therapeutics, Alpha-emitting radioisotopes, Precision medicine / companion diagnostics
Fundamentals
- Price$25.98 as of 2026-08-24 close
- Market cap$1.3B as of 2026-08-24
- P/En/a negative earnings
- Net margin-843.9% as of 2026-08-24
- Gross margin-11.6% as of 2026-08-24
- ROE-47.5% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+49.9% as of 2026-08-24
- Beta1.75 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How AKTS compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Analyst consensus
- Consensus ratingStrong Buy (1.11 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$34.81 range $31.50 – $40.00; median $34.50
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AKTS
- Consensus EPS estimate-$0.441 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Company is unprofitable and clinical-stage, with significant R&D expenses and no approved products; dependent on securing additional capital to fund development programs through clinical trials and potential regulatory approval.","Lead program [225Ac]Ac-AKY-1189 has not yet achieved clinical efficacy or regulatory approval; failure to demonstrate safety and efficacy in trials could result in program termination or significant delays.","Highly competitive field with established radiopharmaceutical programs from larger companies; must successfully differentiate miniprotein platform technology and expand beyond PSMA and somatostatin receptor targets to capture market opportunity."]
Insider activity (SEC Form 4)
0 open-market purchases and 9 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 9 sells ($3M) — 3 selling insiders
- Last 180 days0 buys · 9 sells ($3M) — 3 selling insiders
Cluster buying: 6 different insiders reported open-market purchases (SEC code P) of AKTS within a 30-day window between 2026-01-12 and 2026-01-12. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-20. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AKTS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding AKTS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 3,001,759
- Reported value $53,701,468
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AKTS had 3,470,122 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for AKTS because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 3,470,122
- Prior settlement (shares) 3,741,161
- Reported change -7.24%
- Days to cover (reported) 12.84
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Novartis (NVS) — radiopharmaceutical programs (PSMA, somatostatin receptor)
- Lantheus Holdings (LNTH) — radiopharmaceutical technology and imaging
- Telix Pharmaceuticals (TLXA) — targeted radiopharmaceuticals and imaging agents
- Seagen / Pfizer (PFE) — Padcev (nectin-4 targeting antibody-drug conjugate)
- Genmab (GMAB) — ADC and radiopharmaceutical programs
- Myriad Genetics — companion diagnostics and radiopharmaceuticals
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AKTS vs…
Frequently asked questions
What does AKTIS ONCOLOGY INC (AKTS) do?
Aktis Oncology is a clinical-stage oncology company focused on developing targeted radiopharmaceuticals using proprietary miniprotein radioconjugate technology. The company's lead program targets Nectin-4 with [225Ac]Ac-AKY-1189, a miniprotein conjugated to the alpha-emitting radioisotope actinium-225, designed for treatment of locally advanced or metastatic urothelial cancer and other Nectin-4-expressing solid tumors.
What sector is AKTIS ONCOLOGY INC (AKTS) in?
AKTIS ONCOLOGY INC (AKTS) is classified in the Health Care sector. Its industry is Targeted radiopharmaceuticals / radiotherapy oncology. It trades on NASDAQ.
Who are AKTIS ONCOLOGY INC's (AKTS) competitors?
Notable peers of AKTIS ONCOLOGY INC (AKTS) include Novartis (NVS) — radiopharmaceutical programs (PSMA, somatostatin receptor), Lantheus Holdings (LNTH) — radiopharmaceutical technology and imaging, Telix Pharmaceuticals (TLXA) — targeted radiopharmaceuticals and imaging agents, Seagen / Pfizer (PFE) — Padcev (nectin-4 targeting antibody-drug conjugate) and Genmab (GMAB) — ADC and radiopharmaceutical programs. This peer set is informational only — not financial advice.
Where does stocks-llm's data on AKTS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.